Rare Disease Drug Launch – Lessons Learned to Ensure Success is Not a Rare Event

Rare disease drug launches are more common than ever. Commercial teams will continue to need rare disease drug launch expertise, as over a third of industry R&D pipeline are orphan drugs. Preparing for a rare disease drug launch is more challenging than ever before with increased competition, price pressures, and customer expectations. Success in rare disease drug launch depends on early preparation, tailored strategy, and an exquisite understanding of and responsiveness to customer needs.

With a $131 billion market valuation and 11% growth rate, it’s clear why rare disease product launch has increased. Commercial attractiveness of rare disease drug launches stems from high price points, increased exclusivity and R&D tax and cost benefits. Orphan drug designation enables 7-10-year market exclusivity and an asset can hold orphan designations across several indications.

This webinar will focus on key challenge areas and critical success factors in rare disease launch readiness including accurate opportunity sizing, engaging advocates, managing accelerated review timelines and access challenges. Our industry and professional services speakers will share lessons learned from real examples of rare disease launch readiness efforts.

Speakers

Beth Schurman, Partner, Herspiegel Consulting

Beth Schurman has helped to grow Herspiegel Consulting during the last 12 years into a world-class firm helping clients with commercial strategy, innovation, and execution. She has been involved in new product commercialization and brand optimization across oncology, CNS, metabolic disease, dermatology, women’s and men’s’ health from rare disease to blockbuster brands. Prior to Herspiegel Consulting, Schurman worked on the client side in marketing roles at Bristol-Myers Squibb and Novo Nordisk.

Message Presenter

Jennifer Beachell, Vice President Commercial, Momenta Pharmaceuticals

Jen Beachell is the vice president of global commercial strategy at Momenta Pharmaceutical. Beachell has led commercial organizations and teams over a 20-year career in the biopharma industry. At Momenta, Beachell and the team are preparing to launch nipocalimab across three indications in different therapeutic areas, including hemolytic disease of the fetus and newborn, a rare disease that affects pregnant women and families. Beachell’s expertise spans the commercial disciplines of market access, pricing, positioning, sales, promotion, and patient services. Beachell is recognized as a commercialization expert with both early strategy and late stage experience, including launching Benysta, FluMist, OrthoVisc, and relaunching Juxtapid and Myalept. Beachell also has a background in digital health, direct-to-consumer marketing and healthcare policy.

Message Presenter